SEC Filing Summary
Filing mismatch: The request identifies PALISADE BIO, INC., but the provided Form 10-K is for Neuralstem, Inc. The summary below reflects the provided filing.
Business Context and Reporting Period
Neuralstem is a clinical-stage biopharmaceutical company developing human neural stem-cell therapies and small-molecule compounds for central nervous system disorders. Its principal programs were NSI-189 for major depressive disorder and NSI-566 for ALS, ischemic stroke, and chronic spinal cord injury.
The filing covers the fiscal year ended December 31, 2016. All share and per-share information was retrospectively adjusted for a 1-for-13 reverse stock split effective January 6, 2017.
Financial Performance and Position
| Metric | 2016 | 2015 | Change |
|---|---|---|---|
| Revenue | $16,246 | $10,417 | Increase; no product sales |
| Research and development expense | $13.16 million | $12.64 million | Increase of 4% |
| General and administrative expense | $7.50 million | $6.53 million | Increase of 15% |
| Total operating expenses | $20.65 million | $19.17 million | Increase of 8% |
| Operating loss | $20.64 million | $19.16 million | Higher loss |
| Net loss | $21.07 million | $20.90 million | Higher loss |
| Basic and diluted loss per share | $2.53 | $2.99 | Improved due primarily to higher share count |
| Net cash used in operating activities | $15.62 million | $18.93 million | Usage decreased 18% |
Revenue consisted primarily of intellectual-property licensing fees and approximately $6,000 of royalties related to a prior patent-infringement settlement. The company had no significant commercial product revenue and remained unprofitable.
At December 31, 2016, cash and cash equivalents were $15.19 million, short-term investments were $5.00 million, and total liquidity was approximately $20.19 million. Working capital was approximately $13.57 million and stockholders’ equity was approximately $11.33 million.
Current liabilities were $7.33 million. The balance sheet showed no long-term debt after current classification, but approximately $3.77 million of remaining principal payments under the loan were due in 2017. The company also reported a $3.92 million derivative liability related to stock purchase warrants.
Material Changes Versus the Prior Comparable Period
- Operating expenses increased by approximately $1.49 million, driven by higher research and development, legal and professional, compensation, severance, and financing-related costs.
- Research and development expense increased 4%, primarily from higher salaries, benefits, severance, bonuses, and stock-based compensation.
- General and administrative expense increased 15%, including higher legal and professional fees related to financing, licensing, and Nasdaq compliance.
- Interest expense declined to $1.14 million from $1.82 million, while 2016 included a $458,608 gain on a related-party settlement and a $660,253 gain from changes in derivative fair value.
- Operating cash use improved by $3.32 million, while financing cash inflows increased substantially to $23.74 million from $3.89 million.
- The company raised approximately $28.1 million net through securities offerings and repaid approximately $4.6 million of long-term debt.
- In December 2016, Tianjin Pharmaceutical Group invested $20.0 million gross through the purchase of common stock and Series A convertible preferred stock. The preferred stock was convertible into approximately 3.89 million common shares, subject to ownership limitations.
- Management announced a cost-reduction plan and reduction in force in May 2016, resulting in approximately $470,000 of severance and stock-option modification costs.
Guidance, Outlook, Risks, and Unusual Items
Management estimated an average monthly cash burn of approximately $2.1 million during the first half of 2017, reflecting ongoing clinical trials and debt repayment, and approximately $800,000 during the second half after anticipated completion of the major depressive disorder study and final debt repayments. Based on these assumptions, management expected existing liquidity to fund operations into the second quarter of 2018.
The company stated that it expected additional financing to be necessary and did not expect profitability for the next several years. Potential funding sources included equity or debt offerings, licensing arrangements, collaborations, and grants, but no future funding commitments existed.
NSI-189 was in a 220-subject Phase 2 randomized, placebo-controlled trial for major depressive disorder. The first subject was enrolled in May 2016, and the company announced 50% enrollment in September 2016. The filing stated that results were expected in the third quarter of 2017; enrollment was subsequently completed in February 2017.
The company strategically refocused resources primarily on NSI-189 and sought external funding to defray substantially all costs of the NSI-566 stem-cell program. There was no assurance that such funding would be secured.
Key risks include continued operating losses, dependence on additional financing, clinical-trial failure or delay, uncertain FDA and foreign regulatory approval, reliance on third-party manufacturers and clinical-research providers, intellectual-property challenges, competition, product-liability exposure, and potential dilution from future securities issuances.
The 2015 auditor’s report included substantial doubt about the company’s ability to continue as a going concern. The 2016 auditor’s report did not include a going-concern qualification because 2016 financing was considered sufficient to fund planned operations for at least one year; management nevertheless stated that continued operations remained dependent on additional financing.
Other unusual items included the related-party reimbursement agreement under which a former executive agreed to repay approximately $658,000 over six years, a $459,000 related non-operating gain, the reverse stock split, and Nasdaq minimum-bid-price compliance concerns.
Most Important Facts to Verify
- Confirm the issuer identity: the supplied filing is Neuralstem, Inc., not Palisade Bio, Inc.
- Verify the company’s approximately $20.2 million liquidity balance against the projected cash burn and second-quarter 2018 funding horizon.
- Review the terms, conversion rights, ownership limitations, and potential dilution associated with the Series A preferred stock and outstanding warrants.
- Assess the remaining 2017 debt obligations, including the approximately $2.8 million balloon payment due in April 2017.
- Track Phase 2 NSI-189 results and determine whether efficacy and safety support further development.
- Evaluate whether external funding for NSI-566 was obtained and whether the stem-cell programs continued without material delays.
- Review future financing needs, potential dilution, Nasdaq listing compliance, and the effect of the 1-for-13 reverse stock split on liquidity.